Imagine if you could save all the world's digital files inside a tiny drop of liquid instead of massive, power-hungry server farms. This technology uses a computer chip to 'write' binary data into DNA strands using natural enzymes. It's like replacing a giant warehouse of hard drives with a few microscopic vials that last for ages.
Current data storage relies on fossil-fuel-dependent hardware that consumes massive energy and lacks the density to handle the coming exabytes of data. There is an urgent need for a writing technology that is fast, cheap, and sustainable.
A proof-of-concept writing technology using a dense CMOS semiconductor chip to control enzymatic DNA synthesis.
If you are a data center provider dealing with skyrocketing energy costs and physical space limits — this project developed a DNA writing technology that aims for terabyte capacity and MB/s writing speed. This allows for massive data archiving with a reduced physical footprint and lower power requirements.
If you are a government agency dealing with the need to preserve critical records for centuries without degradation — this project developed an enzymatic DNA synthesis method. It provides a sustainable way to store exabytes of data without relying on fossil-fuel-dependent hardware refreshes.
If you are a biotech firm dealing with the high cost and slow speed of outsourced chemical DNA synthesis — this project developed a semiconductor-based enzymatic writing tool. This enables faster, high-purity DNA production on-site using a CMOS chip.
The project aims to create an affordable and scalable storage solution that reduces cost requirements relative to conventional technologies. Based on available project data, it seeks to replace chemical-intensive models with a more economical enzymatic process.
Yes, the objective is to demonstrate high-density chip multiplexing to achieve performances like terabyte capacity and MB/s writing speeds. The long-term goal is to scale into the exabyte regime.
The project is coordinated by DNA Script SAS, which utilizes a patented enzymatic synthesis cycle. Specific licensing terms for the Hyperion results are not detailed in the provided data.
The research project runs from 2023-09-01 to 2027-08-31. Once the proof of principle is validated during this period, the approach will become the basis for deployable technologies.
The technology uses a very dense semiconductor integrated circuit (CMOS chip) to control DNA synthesis. It is designed to be deployable in data centers or similar settings.
The project is uniquely structured as a single-partner consortium consisting of one French SME, DNA Script SAS. This indicates a high level of confidence in the company's internal R&D capabilities and a streamlined decision-making process, as the industry ratio is 100%.
Contact DNA Script SAS in Paris, France
Contact us to track the transition of HYPERION from proof-of-concept to industrial pilot.
